ImmunoGen, Inc. (0A8K.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
ImmunoGen, Inc.
Address
830 Winter Street
Waltham, MA 02451-1477
United States of America (the)
Phone
781 895 0600
Sector
Healthcare
Industry
Biotechnology
Employees
277
First IPO Date
April 14, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Mark Joseph Enyedy | President, Chief Executive Officer & Director | 1.28M | 1964 |
| Michael J. Vasconcelles | Chief Medical Officer | 304,620 | 1963 |
| Lauren A. White | Senior Vice President & Chief Financial Officer | 537,532 | 1979 |
| Theresa G. Wingrove | Senior Vice President of Regulatory Affairs & Quality | 548,205 | 1958 |
| Stacy A. Coen | Senior Vice President & Chief Business Officer | 584,042 | 1971 |
| Anabel Chan | Head of Investor Relations | 0 | N/A |
| Audrey Bergan | Senior Vice President & Chief HR Officer | 0 | N/A |
| Courtney O'Konek | Senior Director of Corporation Communications & Investor Relations | 0 | N/A |
| Isabel Kalofonos | Senior Vice President & Chief Commercial Officer | 0 | N/A |
| Daniel S. Char | Senior Vice President, Chief Legal Officer & Secretary | 0 | 1962 |
Description
ImmunoGen, Inc. is a biotechnology firm currently in the clinical development phase, specializing in the creation of antibody-drug conjugates (ADCs) designed for cancer treatment. Among its pipeline, mirvetuximab soravtansine is a prominent ADC, presently undergoing Phase III clinical trials, aimed at platinum-resistant ovarian cancer by targeting folate-receptor alpha (FRa). Another key candidate, Pivekimab sunirine, an ADC designed to target CD123, is progressing through Phase II trials for the management of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. In its earlier-stage research, the company is advancing IMGC936, an ADC being co-developed with MacroGenics, Inc., alongside IMGN151, another anti-FRa candidate. ImmunoGen maintains strategic partnerships with several pharmaceutical and biotech entities, including Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Established in 1980, ImmunoGen, Inc. operates from its headquarters in Waltham, Massachusetts.
